Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Mauvais-Jarvis et al., Endocrinology, doi:10.1210/endocr/bqab114 (Review)
Mauvais-Jarvis et al., Do Anti-androgens Have Potential as Therapeutics for COVID-19?, Endocrinology, doi:10.1210/endocr/bqab114 (Review)
Jun 2021   Source   PDF  
  All Studies   Meta
Review of research related to the potential benefits of anti-androgrens for COVID-19.
Mauvais-Jarvis et al., 5 Jun 2021, peer-reviewed, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: Endocrinology, 2021, Vol. 162, No. 8, 1–4 doi:10.1210/endocr/bqab114 Perspective Perspective Franck Mauvais-Jarvis1,2,3 1 Department of Medicine, Section of Endocrinology, Tulane University School of Medicine, New Orleans, LA, USA; 2Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA, USA; and 3 Southeast Louisiana VA Medical Center, New Orleans, LA, USA ORCiD number: 0000-0002-0874-0754 (F. Mauvais-Jarvis). Received: 29 April 2021; Editorial Decision: 1 June 2021; First Published Online: 5 June 2021; Corrected and Typeset: 7 July 2021. Abstract Coronavirus disease 2019 (COVID-19) is characterized by a gender disparity in severity, with men exhibiting higher hospitalization and mortality rates than women. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, infects cells following recognition and attachment of the viral spike glycoprotein to the angiotensin-converting enzyme 2 transmembrane protein, followed by spike protein cleavage and activation by cell surface transmembrane protease serine 2 (TMPRSS2). In prostate cancer cells, androgen acting on the androgen receptor increases TMPRSS2 expression, which has led to the hypothesis that androgen-dependent expression of TMPRSS2 in the lung may increase men’s susceptibility to severe COVID-19 and that, accordingly, suppressing androgen production or action may mitigate COVID-19 severity by reducing SARS-CoV-2 amplification. Several ongoing clinical trials are testing the ability of androgen deprivation therapies or anti-androgens to mitigate COVID-19. This perspective discusses clinical and molecular advances on the rapidly evolving field of androgen receptor (AR) action on cell surface transmembrane protease serine 2 (TMPRSS2) expression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of anti-androgens on coronavirus disease 2019 (COVID-19) severity in male patients. It discusses limitations of current studies and offers insight for future directions. Key Words: androgens, testosterone, TMPRSS2, ACE2, SARS-CoV-2, COVID-19, sex differences As of June 2021, with over 170 000 000 confirmed cases of COVID-19 worldwide, the percentage of confirmed cases is equal among men and women. However, among more than 3 500 000 deaths globally, for every 10 female confirmed cases that have died from COVID-19, there are 15 males (https:// the-data-tracker/). Several mechanisms have been proposed to explain this relative female protection from severe COVID-19 outcomes, with the most likely being related to women’s more robust immune response to viruses (1). SARS-CoV-2 entry and infection of cells is mediated by recognition and attachment of the viral spike glycoprotein ISSN Online 1945-7170 © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail:   1 Do Anti-androgens Have Potential as Therapeutics for COVID-19? 2 evidence indicates that ADT prevents COVID-19 infection or mitigates COVID-19 severity. Thus, several randomized clinical trials (RCTs) have begun to test the efficacy of ADT in the general population of male COVID-19 patients. The most interesting to..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop